TAIHO ONCOLOGY
PharmaTAIHO ONCOLOGY is a pharmaceutical company focused on Oncology, Gastroenterology. Key products include INQOVI.
FDA Novel Drug Designations
(2020-2022)TAIHO ONCOLOGY's Key Drugs
TAIHO ONCOLOGY's core commercial portfolio centers on INQOVI, LONSURF, spanning Oncology and Gastroenterology — its most strategically important drugs approved in the last 15 years.
TAIHO ONCOLOGY's Recent FDA Approvals
New NDA/BLA approvals for TAIHO ONCOLOGY over the last two years — novel drugs only, excluding generics and label supplements.
TAIHO ONCOLOGY's Therapeutic Areas
TAIHO ONCOLOGY's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Gastroenterology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
TAIHO ONCOLOGY's Top Competitors
TAIHO ONCOLOGY's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
TAIHO ONCOLOGY Pipeline Snapshot
TAIHO ONCOLOGY has 54 active clinical programs from ClinicalTrials.gov — 8 Phase 3, 15 Phase 2 and 31 Phase 1.
Phase 3 Readout Calendar Pro
4 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 3/7 completed
- • Speed: 43 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges